|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
S100 beta, a calcium binding astrocytic brain protein, influences hippocampal long-term potentiation (LTP) and depression (LTD), synaptic processes suggested to play role in spatial (contextual) learning and memory.
|
8840925 |
1996 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
S100 beta, a calcium binding brain protein expressed by astrocytes, has been shown to be involved in higher neural processes, including hippocampal-dependent behavioral traits and hippocampal neuronal long-term potentiation (LTP) and depression (LTD), neurophysiological phenomena that may be involved in exploring, learning and remembering novel stimuli.
|
8804639 |
1996 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
PSYGENET |
S100 beta, a calcium binding astrocytic brain protein, influences hippocampal long-term potentiation (LTP) and depression (LTD), synaptic processes suggested to play role in spatial (contextual) learning and memory.
|
8840925 |
1996 |
|
Myocardial Infarction
|
0.530 |
Biomarker
|
disease |
BEFREE |
Knocking out S100B, augmented hypertrophy, decreased apoptosis and preserved cardiac function following myocardial infarction.
|
20204434 |
2011 |
|
Myocardial Infarction
|
0.530 |
Biomarker
|
disease |
RGD |
These results suggest that interaction of RAGE and its ligand S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53 signaling.
|
19910580 |
2010 |
|
Myocardial Infarction
|
0.530 |
Biomarker
|
disease |
BEFREE |
These results suggest that interaction of RAGE and its ligand S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53 signaling.
|
19910580 |
2010 |
|
Myocardial Infarction
|
0.530 |
Biomarker
|
disease |
BEFREE |
We now extend this work by showing that S100beta is induced in hearts of human subjects after myocardial infarction.
|
9788975 |
1998 |
|
Myocardial Infarction
|
0.530 |
Biomarker
|
disease |
CTD_human |
We now extend this work by showing that S100beta is induced in hearts of human subjects after myocardial infarction.
|
9788975 |
1998 |
|
Hematoma
|
0.500 |
Biomarker
|
phenotype |
RGD |
S100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH.
|
19147496 |
2009 |
|
Hematoma
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
The single measurement of serum S100B at 6 h after ICH induction was significantly correlated with brain edema formation and the maximal extent of the hematoma volumes.
|
19027832 |
2009 |
|
Brain Edema
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
The single measurement of serum S100B at 6 h after ICH induction was significantly correlated with brain edema formation and the maximal extent of the hematoma volumes.
|
19027832 |
2009 |
|
Brain Edema
|
0.500 |
Biomarker
|
phenotype |
RGD |
S100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH.
|
19147496 |
2009 |
|
Depression, Bipolar
|
0.500 |
Biomarker
|
disease |
CTD_human |
Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia.
|
16476148 |
2006 |
|
Manic Disorder
|
0.500 |
Biomarker
|
disease |
CTD_human |
Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia.
|
16476148 |
2006 |
|
Depression, Bipolar
|
0.500 |
Biomarker
|
disease |
CTD_human |
Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain.
|
15581912 |
2004 |
|
Depression, Bipolar
|
0.500 |
Biomarker
|
disease |
RGD |
Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain.
|
15581912 |
2004 |
|
Manic Disorder
|
0.500 |
Biomarker
|
disease |
RGD |
Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain.
|
15581912 |
2004 |
|
Manic Disorder
|
0.500 |
Biomarker
|
disease |
CTD_human |
Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain.
|
15581912 |
2004 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum S100B can be used as a biomarker of depression.
|
30745657 |
2020 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that ethnicity or race should be given serious consideration when studying and interpreting S100b levels in persons with schizophrenia.
|
31786729 |
2020 |
|
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ANCOVA analysis followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels, adjusted for depression severity, pain levels and use of analgesics according different pathologies.
|
31100426 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using a cohort of 86 pregnant women, we found that SSRIs significantly increase BDNF levels in late pregnancy and that S100B, but not BDNF, is associated with maternal depression in SSRI-treated women only.
|
30506371 |
2019 |
|
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with S100B levels in the intermediate tertile, that is, between 33 ng/L and 53 ng/L, had higher odds on remission, odds ratio: 5.5 (95%Confidence Interval (CI): 1.55-19.20, p = <0.01), and were more likely to remit from depression over time, hazard ratio: 1.96 (95%CI: 1.04-3.72, p = 0.04), compared with patients in the lowest tertile.
|
31493698 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment.
|
31554266 |
2019 |
|
Down Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review addresses this novel scenario, presenting data indicating that S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease: acute brain injury (ischemic/hemorrhagic stroke, traumatic injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis), congenital/perinatal disorders (Down syndrome, spinocerebellar ataxia-1), psychiatric disorders (schizophrenia, mood disorders), inflammatory bowel disease.
|
30144068 |
2019 |